News

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...
Novavax stock rises after promising H5N1 vaccine preclinical results
Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...
Zacks Investment Research on MSN2h
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax (NVAX) closed the most recent trading day at $7.64, moving -2.55% from the previous trading session. This move lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow experienced a drop ...
Stocktwits on MSN7h
Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued
Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate induced robust immune responses in nonhuman primates. H5N1 is a highly ...
Undark Magazine15h
RFK Jr’s Vaccine Policies Could Undermine Coverage — and Trust
A series of recent changes could have significant implications for how Americans receive and pay for their shots.